Lessons from Cohort Studies of Targetable Metabolic Deficiencies in Lung Cancer

Abstract

Summary MTAP loss is among the most common potentially targetable driver mutations in NSCLC. Early phase clinical trials are ongoing. Although susceptible to various biases, retrospective studies may serve as a historical control to interpret single arm studies. Combination therapies and novel biomarkers may also improve objective response rates.